Table I.
Characteristics of included randomized controlled trials
| Trial information | Adverse events | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study reference | Age | Male gender | Sample | Follow-up Time [months] | Type of cancer | Acute coronary syndromes | Myocardial infarction | Heart failure | Atrial fibrillation | Atrial flutter | Bradycardia | Cardiac arrest | Cardiac tamponade |
| Ferris, 2020 [13]: | Median age | No (%) | |||||||||||
| Intervention: Durvalumab plus Tremelimumab | 61 | 209 (84.6%) | 247 | 34 | Head and neck squamous cell carcinoma | 2 (0.81%) | NR | 1 (0.41%) | NR | 1 (0.41%) | NR | 1 (0.41%) | NR |
| Control: Durvalumab | 59 | 202 (84.2%) | 240 | 0 (0%) | NR | 0 (0%) | NR | 0 (0%) | NR | 0 (0%) | NR | ||
| Larkin, 2015 [14]: | Mean age | No (%) | |||||||||||
| Intervention: Nivolumab plus Ipilimumab | 59 | 206 (65.6%) | 313 | 21 | Melanoma | 0 (0%) | 1 (0.32%) | 1 (0.32%) | 4 (1.28%) | 1 (0.32%) | 0 (0%) | 0 (0%) | 1 (0.32%) |
| Control: Nivolumab | 59 | 202 (63.9%) | 313 | 1 (0.32%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0.32%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Rizvi, 2020 [15]: | Median age | No (%) | |||||||||||
| Intervention: Durvalumab mas tremelimumab | 64 | 113 (69.3%) | 163 | 39 | Non small cell lung cancer | 1 (0.27%) | 2 (0.54%) | 1 (0.27%) | 5 (1.35%) | 1 (0.27%) | 0 (0%) | 1 (0.27%) | 0 (0%) |
| Control: Durvalumab | 65 | 118 (72.4%) | 163 | 0 (0%) | 0 (0%) | 1 (0.27%) | 2 (0.54%) | 0 (0%) | 1 (0.27%) | 0 (0%) | 1 (0.27%) | ||
| Postow, 2015 [16]: | Median age | No (%) | |||||||||||
| Intervention; Nivolumab plus Ipilimumab | 64 | 63 (66%) | 95 | 18 | Melanoma | NR | NR | NR | 1 (1.6%) | NR | NR | NR | NR |
| Control: Ipilimumab | 67 | 32 (68%) | 47 | NR | NR | NR | 1 (2.17%) | NR | NR | NR | NR | ||
NR – not reported.